We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock
ATXI

Delisted

ATXI was delisted on the 18th of March, 2025.

Back to rankings

31 hedge funds and large institutions have $29.7M invested in Avenue Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

6% more capital invested

Capital invested by funds: $28.1M → $29.7M (+$1.58M)

9% less funds holding

Funds holding: 34 → 31 (-3)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Holders
31
Holders Change
-3
Holders Change %
-8.82%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
8
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.33M
2
Northern Trust
Northern Trust
Illinois
+$535K
3
BRWA
B. Riley Wealth Advisors
Florida
+$474K
4
BlackRock
BlackRock
New York
+$255K
5
MAM
Martingale Asset Management
Massachusetts
+$219K

Top Sellers

Rank Fund Capital Flow
1
KCM
Kennedy Capital Management
Missouri
-$649K
2
OM
Opaleye Management
Massachusetts
-$547K
3
Renaissance Technologies
Renaissance Technologies
New York
-$510K
4
Osaic Holdings
Osaic Holdings
Arizona
-$363K
5
MSL
Mackay Shields LLC
New York
-$272K
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
1
Opaleye Management
Massachusetts
$10.7M -$547K -45 -5%
Vanguard Group
2
Vanguard Group
Pennsylvania
$6.98M +$2.33M +192 +50%
BlackRock
3
BlackRock
New York
$3.71M +$255K +21 +7%
BRWA
4
B. Riley Wealth Advisors
Florida
$1.58M +$474K +39 +43%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.27M – – –
Northern Trust
6
Northern Trust
Illinois
$877K +$535K +44 +157%
Renaissance Technologies
7
Renaissance Technologies
New York
$822K -$510K -42 -38%
State Street
8
State Street
Massachusetts
$794K +$60.8K +5 +8%
EI
9
EAM Investors
California
$778K -$267K -22 -26%
N
10
Nuveen
North Carolina
$332K -$24.3K -2 -7%
Morgan Stanley
11
Morgan Stanley
New York
$246K +$182K +15 +300%
MAM
12
Martingale Asset Management
Massachusetts
$215K +$219K +18 New
Nisa Investment Advisors
13
Nisa Investment Advisors
Missouri
$207K +$207K +17 New
Wells Fargo
14
Wells Fargo
California
$205K +$72.9K +6 +55%
Russell Investments Group
15
Russell Investments Group
United Kingdom
$176K +$170K +14 New
Bank of New York Mellon
16
Bank of New York Mellon
New York
$164K – – –
Charles Schwab
17
Charles Schwab
California
$156K – – –
California State Teachers Retirement System (CalSTRS)
18
California State Teachers Retirement System (CalSTRS)
California
$109K – – –
TRCT
19
Tower Research Capital (TRC)
New York
$75K +$24.3K +2 +50%
New York State Common Retirement Fund
20
New York State Common Retirement Fund
New York
$74K -$24.3K -2 -25%
JP Morgan Chase
21
JP Morgan Chase
New York
$52K -$12.2K -1 -20%
AIG
22
American International Group
New York
$43K – – –
Deutsche Bank
23
Deutsche Bank
Germany
$37K – – –
Barclays
24
Barclays
United Kingdom
$33K – – –
UBS Group
25
UBS Group
Switzerland
$32K -$36.5K -3 -50%
1
2

ATXI Hedge Fund Activity: Q3 2020 in Review

31 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q3 2020, worth a combined $29.7M — up 5.6% from $28.1M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ATXI and 4 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 8 added.

The largest buyer was Vanguard Group, adding an estimated $2.33M. The largest seller was Kennedy Capital Management, exiting entirely with an estimated $649K sold.

  • 31 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q3 2020, down from 34 in Q2 2020.
  • Funds reported $29.7M of Avenue Therapeutics, Inc. Common Stock stock for Q3 2020, up 5.6% quarter-over-quarter.
  • 4 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q3 2020 and 7 closed out, a net change of -3 holders.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q3 2020 was Vanguard Group, an estimated $2.33M added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q3 2020 was Kennedy Capital Management, an estimated $649K sold.

Based on aggregated 13F filings for Q3 2020.